

Study of Nicotinamide Riboside Supplementation in Allogeneic Hematopoietic Cell Transplantation

NCT04332341

Status	RECRUITING
Phase	Early Phase 1
Sponsor	Case Comprehensive Cancer Center
Enrollment	20 participants

Key Eligibility Criteria

Inclusion (4)

- All disease indications for allogeneic hematopoietic cell transplantation except for myelofibrosis.
- Subject must meet program eligibility criteria* for myeloablative conditioning alloHCT and plan to undergo myeloablative conditioning.
- HLA-identical related donor or unrelated human donor source with bone marrow graft.
- Subjects must provide a written informed consent.

Exclusion (3)

- History of allergy or intolerance to NR precursor compounds, including niacin or nicotinamide
- Pregnant or breastfeeding women are excluded from this study since allogeneic HCT is a strict contraindication.
- Subjects with uncontrolled intercurrent illness or psychiatric illness/social situations that would limit compliance with study requirements.

Locations (1 total)

Cleveland Clinic, Case Comprehensive Cancer Center, Cleveland, Ohio, United States